Evaluating Thresholds to Adopt Hypofractionated Preoperative Radiotherapy as Standard of Care in Sarcoma.
Journal
Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
07
2021
accepted:
14
09
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
2
11
2021
Statut:
epublish
Résumé
Data supporting hypofractionated preoperative radiation therapy (RT) for patients with extremity and trunk soft tissue sarcoma (STS) are currently limited to phase II single-institution studies. We sought to understand the type and thresholds of clinical evidence required for experts to adopt hypofractionated RT as a standard-of-care option for patients with STS. An electronic survey was distributed to multidisciplinary sarcoma experts. The survey queried whether data from a theoretical, multi-institutional, phase II study of 5-fraction preoperative RT could change practice. Using endpoints from RTOG 0630 as a reference, the survey also queried thresholds for acceptable local control, wound complication, and late toxicity for the study protocol to be accepted as a standard-of-care option. Responses were logged from 8/27/2020 to 9/8/2020 and summarized graphically. The survey response rate was 55.3% (47/85). Local control is the most important clinical outcome for sarcoma specialists when evaluating whether an RT regimen should be considered standard of care. 17% (8/47) of providers require randomized phase III evidence to consider hypofractionated preoperative RT as a standard-of-care option, whereas 10.6% (5/47) of providers already view this as a standard-of-care option. Of providers willing to change practice based on phase II data, most (78%, 29/37) would accept local control rates equivalent to or less than those in RTOG 0630, as long as the rate was higher than 85%. However, 51.3% (19/37) would require wound complication rates superior to those reported in RTOG 0630, and 46% (17/37) of respondents would accept late toxicity rates inferior to RTOG 0630. Consensus building is needed among clinicians regarding the type and threshold of evidence needed to evaluate hypofractionated RT as a standard-of-care option. A collaborative consortium-based approach may be the most pragmatic means for developing consensus protocols and pooling data to gradually introduce hypofractionated preoperative RT into routine practice.
Identifiants
pubmed: 34720663
doi: 10.1155/2021/3735874
pmc: PMC8556117
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3735874Informations de copyright
Copyright © 2021 Luca F. Valle et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Eur J Surg Oncol. 2014 Dec;40(12):1641-7
pubmed: 25282099
Clin Cancer Res. 2020 Apr 15;26(8):1829-1836
pubmed: 32054730
J Clin Oncol. 1998 Jan;16(1):197-203
pubmed: 9440743
Lancet Oncol. 2020 Oct;21(10):1257-1258
pubmed: 32941793
Lancet Oncol. 2021 Jan;22(1):e2
pubmed: 33387501
J Clin Oncol. 2015 Jul 10;33(20):2231-8
pubmed: 25667281
J Grad Med Educ. 2011 Sep;3(3):285-9
pubmed: 22942950
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1004-1015
pubmed: 29485042
Radiother Oncol. 2016 Apr;119(1):14-21
pubmed: 26718153
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1053-1063
pubmed: 33600887
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Lancet Oncol. 2021 Jan;22(1):e1
pubmed: 33387499
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059428
Lancet Oncol. 2020 Oct;21(10):1366-1377
pubmed: 32941794
J Natl Compr Canc Netw. 2021 Feb 8;:1-12
pubmed: 33556919
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):618-620
pubmed: 31540596
Adv Exp Med Biol. 2019;1123:95-118
pubmed: 31016597
J Clin Oncol. 2005 Oct 1;23(28):7074-80
pubmed: 16192590
Asia Pac J Oncol Nurs. 2017 Jan-Mar;4(1):69-76
pubmed: 28217733
Adv Radiat Oncol. 2020 Jun 29;5(6):1274-1279
pubmed: 33305088
J Natl Cancer Inst. 2000 Feb 2;92(3):269-71
pubmed: 10655446
Radiat Res. 2021 Jul 1;196(1):23-30
pubmed: 33914890
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):674-81
pubmed: 21277106